查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790445

美國生物模擬市場規模、佔有率和趨勢分析報告，按產品、應用、治療領域、部署模型、定價模式、最終用途和細分趨勢分類：2025 年至 2030 年

U.S. Biosimulation Market Size, Share & Trends Analysis Report By Offering (Software, Services), By Application, By Therapeutic Area, By Deployment Model, By Pricing Model, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國生物模擬市場規模與趨勢

預計 2024 年美國生物模擬市場價值將達到 17.8 億美元，預計 2025 年至 2030 年的複合年成長率為 16.2%。

這一成長的關鍵驅動力在於，旨在降低藥物開發成本和縮短開發週期的In Silico模擬建模和模擬工具的應用日益廣泛。隨著新藥上市平均成本的持續上升，製藥和生物技術公司正在利用生物模擬技術來最佳化臨床試驗計劃、預測藥物交互作用，並在研發早期識別潛在的安全隱患。精準醫療日益受到重視，以及對患者個人化給藥策略的需求，進一步推動了對藥理計量學和基於生理的藥物動力學 (PBPK) 建模的需求。

隨著醫療保健產業逐漸轉向更個人化的治療策略，對能夠準確模擬患者特定治療反應的工具的需求日益成長。生物模擬技術使研究人員能夠開發出考慮個體間基因差異的詳細模型，從而預測患者對特定藥物和治療方案的反應。這種方法可以根據每位患者的獨特情況量身定做治療方法，從而提高療效並減少副作用。藥物基因體學組學領域的擴張推動了美國醫療保健產業對能夠將基因數據整合到預測模型中的先進生物模擬工具的需求。

人工智慧和機器學習的進步顯著提升了生物模擬工具的功能。這些技術能夠更準確、更有效率地模擬生物過程，使研究人員能夠準確預測藥物交互作用和療效。將人工智慧和機器學習整合到生物模擬平台中，將有助於開發個人化醫療方法，從而根據患者的個別情況量身定做治療方案。這些技術協同效應正在推動生物模擬在美國藥物開發過程中的應用。

此外，美國藥物管理局（FDA）的積極監管支持也推動了市場成長，該機構擴大接受生物模擬數據作為核准提交的一部分。生技藥品和基因治療方法、細胞療法等複雜療法的興起也促進了市場擴張，因為這些治療方法通常需要先進的建模方法來評估療效和安全性。此外，人工智慧和機器學習與生物模擬平台的整合正在提高模型的準確性和可擴展性，使這些工具在整個藥物開發生命週期中更易於使用且更有價值。

新冠疫情衝擊了美國市場，加速了對模擬軟體和服務的需求，以支持候選疫苗的快速開發和測試。例如，2020年8月，美國生物模擬領域的參與企業Certara與多家製藥公司合作開發了一種新的生物模擬工具，利用虛擬患者和臨床測試，簡化了針對不同患者群體的候選疫苗的開發。這項創新旨在在現實世界的臨床試驗開始之前提供關鍵見解，從而提高疫苗開發的效率和效果。這項新功能已被整合到Certara的定量系統藥理學（QSP）平台中，並凸顯了生物模擬在美國醫療體系的疫情防治工作中日益成長的重要性。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國生物模擬市場分析工具：PESTEL
    • 政治與法律
    • 經濟與社會
    • 科技
    • 環境
    • 社會
  • 科技趨勢
  • 使用案例和見解
  • 美國生物模擬市場分析工具：波特五力分析
  • COVID-19影響分析

第4章美國生物模擬市場（依產品、估價和趨勢分析）

  • 美國生物模擬市場：提供變異分析
  • 美國生物模擬市場：產品細分儀表板
  • 2024 年和 2030 年產品趨勢和市場佔有率分析
  • 透過提供
  • 軟體
    • 分子建模與模擬軟體
    • 臨床試驗設計軟體
    • PK/PD建模和模擬軟體
    • Pbpk建模與模擬軟體
    • 毒性預測軟體
    • 其他軟體
  • 服務
    • 合約服務
    • 諮詢
    • 其他（實施、培訓、支援）

第5章：美國生物模擬市場的應用、預測與趨勢分析

  • 美國生物模擬市場：應用趨勢分析
  • 美國生物模擬市場：應用細分儀表板
  • 2024 年和 2030 年應用趨勢和市場佔有率分析
  • 按用途
  • 藥物研發
  • 疾病模型
  • 其他（精準醫療、毒理學）

第6章：美國生物模擬市場（依治療領域、估價和趨勢分析）

  • 美國生物模擬市場：治療領域差異分析
  • 美國生物模擬市場：治療領域細分儀表板
  • 2024 年和 2030 年治療領域趨勢和市場佔有率分析
  • 按治療領域
  • 腫瘤學
  • 心血管疾病
  • 感染疾病
  • 神經系統疾病
  • 其他

第7章：美國生物模擬市場（按部署模型、估計和趨勢分析）

  • 美國生物模擬市場：部署模型波動分析
  • 美國生物模擬市場：部署模型細分儀表板
  • 2024 年和 2030 年部署模型趨勢和市場佔有率分析
  • 按部署模型
  • 雲端基礎
  • 本地
  • 混合模式

第8章：美國生物模擬市場：定價模式的估算與趨勢分析

  • 美國生物模擬市場：定價模式波動分析
  • 美國生物模擬市場：定價模式細分儀表板
  • 2024 年和 2030 年定價模式趨勢和市場佔有率分析
  • 按定價模式
  • 基於許可證的模型
  • 訂閱模式
  • 基於服務的模型
  • 計量收費模式

第9章美國生物模擬市場：按最終用途的估計和趨勢分析

  • 美國生物模擬市場：最終用途差異分析
  • 美國生物模擬市場：最終用途細分儀表板
  • 2024 年和 2030 年最終用途趨勢和市場佔有率分析
  • 按最終用途
  • 生命科學公司
  • 學術研究機構
  • 其他（CRO/CDMO、監管機構）

第10章 競爭格局

  • 公司分類
  • 2024年企業市場地位/佔有率分析
  • 企業市場占有率分析
  • 公司簡介/上市公司
    • Certara, USA.
    • Dassault Systemes
    • Advanced Chemistry Development
    • Simulation Plus
    • Schrodinger, Inc.
    • Chemical Computing Group ULC
    • Physiomics Plc
    • Rosa & Co. LLC
    • BioSimulation Consulting Inc.
    • Genedata AG
    • Instem Group of Companies
    • PPD, Inc.
    • Yokogawa Insilico BIoTechnology GmbH
Product Code: GVR-4-68040-674-2

U.S. Biosimulation Market Size & Trends:

The U.S. biosimulation market size was estimated at USD 1.78 billion in 2024 and is projected to grow at a CAGR of 16.2% from 2025 to 2030. This growth is primarily driven by the increasing adoption of in silico modeling and simulation tools to reduce drug development costs and timelines. With the average cost of bringing a new drug to market continuing to rise, pharmaceutical and biotech companies are leveraging biosimulation to optimize clinical trial designs, predict drug interactions, and identify potential safety concerns early in the R&D process. The growing emphasis on precision medicine and the need for patient-specific dosing strategies further boost the demand for pharmacometrics and physiologically based pharmacokinetic (PBPK) modeling.

As the healthcare industry moves toward more tailored treatment strategies, a growing demand exists for tools that accurately model patient-specific therapy responses. Biosimulation enables researchers to develop detailed models accounting for genetic variations among individuals, helping predict how different patients respond to particular drugs or treatment plans. This approach improves treatment effectiveness while reducing adverse effects by customizing therapies to each patient's unique profile. The expanding field of pharmacogenomics highlights the critical need for advanced biosimulation tools capable of incorporating genetic data into predictive models within the U.S. healthcare landscape.

Advancements in AI and ML are significantly enhancing the capabilities of biosimulation tools. These technologies allow for more accurate and efficient simulations of biological processes, enabling researchers to predict drug interactions and outcomes precisely. Integrating AI and ML into biosimulation platforms facilitates the development of personalized medicine approaches, where treatments are tailored to individual patient profiles. This technological synergy is driving the adoption of biosimulation in drug development processes across the U.S.

Moreover, favorable regulatory support from the U.S. FDA, which increasingly accepts biosimulation data as part of regulatory submissions, enhances market growth. The rise of biologics and complex therapies, such as gene and cell therapies, has also contributed to the market expansion, as these treatments often require advanced modeling approaches to evaluate efficacy and safety. Moreover, the integration of artificial intelligence and machine learning into biosimulation platforms is enhancing model accuracy and scalability, making these tools more accessible and valuable across the drug development lifecycle.

The COVID-19 pandemic impacted the U.S. market, accelerating the demand for biosimulation software and services to support vaccine candidates' rapid development and testing. For instance, in August 2020, Certara, a player in the U.S. biosimulation sector, partnered with several pharmaceutical companies to develop a new biosimulation tool to streamline vaccine candidate development across diverse patient populations using virtual patients and clinical trials. This innovation aimed to provide critical insights before initiating real-world studies, enhancing the efficiency and effectiveness of vaccine development. This new capability was integrated into Certara's Quantitative Systems Pharmacology (QSP) platform, highlighting the growing importance of biosimulation in pandemic response efforts within the U.S. healthcare system.

U.S. Biosimulation Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. biosimulation market report based on offering, application, therapeutic area, deployment model, pricing model, and end-use.

  • Offering Outlook (Revenue, USD Million, 2018 - 2030)
  • Software
    • Molecular Modeling & Simulation Software
    • Clinical Trial Design Software
    • PK/PD Modeling and Simulation Software
    • Pbpk Modeling and Simulation Software
    • Toxicity Prediction Software
    • Other Software
  • Services
    • Contract Services
    • Consulting
    • Other (Implementation, Training, & Support)
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Drug Discovery & Development
  • Disease Modeling
  • Other (Precision Medicine, Toxicology)
  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Others
  • Deployment Model Outlook (Revenue, USD Million, 2018 - 2030)
  • Cloud-based
  • On-premise
  • Hybrid Model
  • Pricing Model Outlook (Revenue, USD Million, 2018 - 2030)
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Life Sciences Companies
  • Academic Research Institutions
  • Others (CROs/CDMOs, Regulatory Authorities)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Biosimulation Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Offering segment outlook
      • 2.1.2.2. Application segment outlook
      • 2.1.2.3. Therapeutic Area segment outlook
      • 2.1.2.4. Deployment Model segment outlook
      • 2.1.2.5. Pricing Model segment outlook
      • 2.1.2.6. End Use segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Rising prevalence of chronic diseases
      • 3.3.1.2. Growing demand for personalized medicine
      • 3.3.1.3. Technological advancements
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High cost associated with biosimulation technology and software
      • 3.3.2.2. Stringent regulatory requirements
    • 3.3.3. Market Opportunity Analysis
    • 3.3.4. Market Challenges Analysis
  • 3.4. U.S. Biosimulation Market Analysis Tools: PESTEL
    • 3.4.1. Political & Legal
    • 3.4.2. Economic & Social
    • 3.4.3. Technology
    • 3.4.4. Environmental
    • 3.4.5. Social
  • 3.5. Technology Trends
  • 3.6. Case Studies & Insights
  • 3.7. U.S. Biosimulation Market Analysis Tools: Porter's
  • 3.8. Covid-19 Impact Analysis

Chapter 4. U.S. Biosimulation Market: Offering Estimates & Trend Analysis

  • 4.1. U.S. Biosimulation Market: Offering Movement Analysis
  • 4.2. U.S. Biosimulation Market: Offering Segment Dashboard
  • 4.3. Offering Movement & Market Share Analysis, 2024 & 2030
  • 4.4. U.S. Biosimulation Market Estimates & Forecast, by Offering
  • 4.5. Software
    • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.2. Molecular Modeling & Simulation Software
      • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Clinical Trial Design Software
      • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.4. PK/PD Modeling and Simulation Software
      • 4.5.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.5. Pbpk Modeling and Simulation Software
      • 4.5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.6. Toxicity Prediction Software
      • 4.5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.7. Other Software
      • 4.5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.2. Contract Services
      • 4.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3. Consulting
      • 4.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.4. Other (Implementation, Training, & Support)
      • 4.6.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Biosimulation Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Biosimulation Market: Application Movement Analysis
  • 5.2. U.S. Biosimulation Market: Application Segment Dashboard
  • 5.3. Application Movement & Market Share Analysis, 2024 & 2030
  • 5.4. U.S. Biosimulation Market Estimates & Forecast, by Application
  • 5.5. Drug Discovery & Development
    • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.6. Disease Modeling
    • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.7. Other (Precision Medicine, Toxicology)
    • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. U.S. Biosimulation Market: Therapeutic Area Movement Analysis
  • 6.2. U.S. Biosimulation Market: Therapeutic Area Segment Dashboard
  • 6.3. Therapeutic Area Movement & Market Share Analysis, 2024 & 2030
  • 6.4. U.S. Biosimulation Market Estimates & Forecast, by Therapeutic Area
  • 6.5. Oncology
    • 6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.6. Cardiovascular Disease
    • 6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.7. Infectious Disease
    • 6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.8. Neurological Disorders
    • 6.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Biosimulation Market: Deployment Model Estimates & Trend Analysis

  • 7.1. U.S. Biosimulation Market: Deployment Model Movement Analysis
  • 7.2. U.S. Biosimulation Market: Deployment Model Segment Dashboard
  • 7.3. Deployment Model Movement & Market Share Analysis, 2024 & 2030
  • 7.4. U.S. Biosimulation Market Estimates & Forecast, by Deployment Model
  • 7.5. Cloud-based
    • 7.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 7.6. On-premise
    • 7.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 7.7. Hybrid Model
    • 7.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 8. U.S. Biosimulation Market: Pricing Model Estimates & Trend Analysis

  • 8.1. U.S. Biosimulation Market: Pricing Model Movement Analysis
  • 8.2. U.S. Biosimulation Market: Pricing Model Segment Dashboard
  • 8.3. Pricing Model Movement & Market Share Analysis, 2024 & 2030
  • 8.4. U.S. Biosimulation Market Estimates & Forecast, by Pricing Model
  • 8.5. License-based Model
    • 8.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.6. Subscription-based Model
    • 8.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.7. Service-based Model
    • 8.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.8. Pay Per Use Model
    • 8.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 9. U.S. Biosimulation Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Biosimulation Market: End Use Movement Analysis
  • 9.2. U.S. Biosimulation Market: End Use Segment Dashboard
  • 9.3. End Use Movement & Market Share Analysis, 2024 & 2030
  • 9.4. U.S. Biosimulation Market Estimates & Forecast, by End Use
  • 9.5. Life Sciences Companies
    • 9.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 9.6. Academic Research Institutions
    • 9.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 9.7. Others (CROs/CDMOs, Regulatory Authorities)
    • 9.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Company Market Position/Share Analysis, 2024
  • 10.3. Company Share Analysis
  • 10.4. Company Profiles/Listing
    • 10.4.1. Certara, USA.
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments
    • 10.4.2. Dassault Systemes
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments
    • 10.4.3. Advanced Chemistry Development
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments
    • 10.4.4. Simulation Plus
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments
    • 10.4.5. Schrodinger, Inc.
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments
    • 10.4.6. Chemical Computing Group ULC
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments
    • 10.4.7. Physiomics Plc
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments
    • 10.4.8. Rosa & Co. LLC
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments
    • 10.4.9. BioSimulation Consulting Inc.
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments
    • 10.4.10. Genedata AG
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments
    • 10.4.11. Instem Group of Companies
      • 10.4.11.1. Participant's Overview
      • 10.4.11.2. Financial Performance
      • 10.4.11.3. Product Benchmarking
      • 10.4.11.4. Recent Developments
    • 10.4.12. PPD, Inc.
      • 10.4.12.1. Participant's Overview
      • 10.4.12.2. Financial Performance
      • 10.4.12.3. Product Benchmarking
      • 10.4.12.4. Recent Developments
    • 10.4.13. Yokogawa Insilico Biotechnology GmbH
      • 10.4.13.1. Participant's Overview
      • 10.4.13.2. Financial Performance
      • 10.4.13.3. Product Benchmarking
      • 10.4.13.4. Recent Developments

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. biosimulation market revenue estimates and forecast, by offering, 2018 - 2030 (USD Million)
  • Table 4 U.S. biosimulation market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. biosimulation market revenue estimates and forecast, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6 U.S. biosimulation market revenue estimates and forecast, by deployment model, 2018 - 2030 (USD Million)
  • Table 7 U.S. biosimulation market revenue estimates and forecast, by pricing model, 2018 - 2030 (USD Million)
  • Table 8 U.S. biosimulation market revenue estimates and forecast, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S Biosimulation Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for Market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Type segment outlook
  • Fig. 11 Application segment outlook
  • Fig. 12 Distribution Channel segment outlook
  • Fig. 13 Competitive landscape
  • Fig. 14 U.S Biosimulation Market: Market dynamics
  • Fig. 15 U.S Biosimulation Market: Porter's analysis
  • Fig. 16 U.S Biosimulation Market: PESTLE analysis
  • Fig. 17 U.S Biosimulation Market: Offering segment dashboard
  • Fig. 18 U.S Biosimulation Market: Offering movement share analysis
  • Fig. 19 Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 20 Molecular Modeling & Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 21 Clinical Trial Design Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 22 PK/PD Modeling and Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 23 Pbpk Modeling and Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 24 Toxicity Prediction Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 25 Other Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 26 Services Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 27 Contract Services Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 28 Consulting Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 29 Other (Implementation, Training, & Support) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 30 U.S Biosimulation Market: Application segment dashboard
  • Fig. 31 U.S Biosimulation Market: Application Movement Share Analysis
  • Fig. 32 Drug Discovery & Development Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 33 Disease Modeling Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 34 Other (Precision Medicine, Toxicology) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 35 U.S Biosimulation Market: Therapeutic Area Segment Dashboard
  • Fig. 36 U.S Biosimulation Market: Therapeutic Area Movement Share Analysis
  • Fig. 37 Oncology Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 38 Cardiovascular Disease Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 39 Infectious Disease Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 40 Neurological Disorders Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 41 Others Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 42 U.S Biosimulation Market: Deployment Model Segment Dashboard
  • Fig. 43 U.S Biosimulation Market: Deployment Model Movement Share Analysis
  • Fig. 44 Cloud-based Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 45 On-premise Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 46 Hybrid Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 47 U.S Biosimulation Market: Pricing Model Segment Dashboard
  • Fig. 48 U.S Biosimulation Market: Pricing Model Movement Share Analysis
  • Fig. 49 License-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 50 Subscription-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 51 Service-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 52 Pay Per Use Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 53 U.S Biosimulation Market: End Use Segment Dashboard
  • Fig. 54 U.S Biosimulation Market: End Use Movement Share Analysis
  • Fig. 55 Life Sciences Companies Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 56 Academic Research Institutions Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 57 Others (CROs/CDMOs, Regulatory Authorities) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 58 Company categorization
  • Fig. 59 Company Market position analysis, 2024
  • Fig. 60 Strategic framework